BioSpace News Archive

Premier Research today announced that it has acquired Health Decisions, a Durham, N.C.-based contract research organization (CRO) focused on clinical development in all areas of women’s health and diagnostics

Guided Therapeutics, Inc. announced today its Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation (SMI), has received notice from the Jinan Medical Device Quality Supervision and Testing Center of the State Food and Drug Administration that LuViva has passed safety and electromagnetic compliance requirements necessary to be used in clinical trials.

Neuspera Medical Inc. today announced the closing of the company’s $65 million series C equity financing. The Series C round was co-led by Vertex Ventures HC and Treo Ventures.

Sesen Bio announced today that the first patient has been enrolled in China in the clinical trial to assess the efficacy and safety of Vicineum in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Series to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes

Neogen Corporation (NASDAQ: NEOG) announced today the results for its fourth quarter and full 2021 fiscal year, which ended May 31, 2021.

– MARIO-3 Phase 2 study evaluating eganelisib added to standard of care Tecentriq ® and Abraxane ® regimen in frontline triple negative breast cancer (TNBC)–

NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® device has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for treating the symptoms of fibromyalgia in adults.

Assertio Holdings, Inc. announced that it will release second quarter 2021 financial results on Thursday, August 5, 2021, after the close of markets.

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, announced that the results of the long-term, open-label extension (OLE) of a randomized, double-blind, placebo-controlled study of cenobamate (C013) have been published online by the journal Epilepsia.